alexa Circulating Cancer Cells And Their Use In The Real Life
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th World Congress on Cancer Science & Therapy
October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Renata Dobrila-Dintinjana
ScientificTracks Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.033
Abstract
CTC?s are cancer cells of solid tumor origin found in the peripheral blood of patients with advanced stages of most types of solid cancers. CTC?s are very rare and represent a surrogate biomarker of hematogenous metastases. Disseminated cancer cells (DTC?s) represent post-extravasation phase and can be found in bone marrow . DTC/CTC detection therefore can be used as a strong prognostic factor, so called minimal residual disease. CTCs have procoagulant phenotypes and strongly determine local thrombin concentration leading to risk of developing thrombosis. CTCs also interfere with host immune cells and platelets which release angiogenic and growth factors (VEGF, PDGF, TGF-beta) what lead to tumor growth and establishment of metastatic tumor sites . CTCs express hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF), and VEGF receptor (VEGFR2), associated with angiogenesis and tumor progression. CTCs detection is an independent, strong prognostic factor for Overall Survival (OS) and predictor of Progression Free Survival (PFS) in patients with metastatic breast cancer, prostate cancer and advanced colorectal cancer . The standardized method for detection CTC in blood is an automated immunomagnetic enrichment and staining system for CTCs (the CellSearch? system). It performs automated immunomagnetic epithelial cell adhesion molecule (EpCAM)- based enrichment followed by CK staining of CTCs in blood samples. The main target organ for the metastatic process in colon cancer is liver. Therefore the portal flow can represent a ?post-intravasation highway? for CTC?s. Meta-analysis of nine studies that used molecular detection (646 patients) concluded that CTC?s detection in portal flow correlate with nodal invasion, and that CTC?s status during surgery for primary tumor correlate with further liver metastatic relapse, neverthless of tumor stage. Also, in other gastrointestinal carcinomas, presence of CTCs means worse prognosis. CTCs can estimate the risk of metastating disease (prognostic information), and identificating therapeutic targets (diagnostic information) and resistance mechanisms. CTCs is perfect alternative to invasive biopsies for early detection of metastatic tumor tissue, and to better assess responses to treatment (liquid biopsy). Molecular profiling of CTCs has the potential to provide individualisation of cancer therapy. Most of the current strategies for detecting CTC are based on the epithelial markers, epithelial cell adhesion molecule and keratin; however, in certain tumor types, these epithelial markers are downregulated during tumor cell dissemination, hampering the detection of CTCs. The optimal cut-off for the number of CTCs associated with worse prognosis is still not established. Low number of CTCs is also restriction for proper evaluation of therapy response. The fact that described patients with breast cancer dormancy who had detectable CTCs had not relapsed even after a follow-up of >20 years makes the potential benefit of this tool questionable. Also, if patient has two cancers (breast, colorectal), one or both can be metastatic; than the interpretation of CSCs results is regardless of origin of the disease. CTC?s presence during treatment also means that it?s a cancer with primary resistency for therapy. Shall we stopp harmfull and unusefull therapy? Can we define subpopulation of patients with the highest treatment benefit trough the CTCs measurements? Does procoagulant nature of CTCs has impact on cancer progres ? Is cancer-response on anticancer therapy also related to antithrombotic therapies? Key to answer these and many other questions is in the incorporation of CTCs into prospective clinical trials to test their clinical utility and there is no doubt that CTCs can become usefull diagnostic and prognostic tool for patients with cancers. We can conclude that CTCs will provide new insight into the biology of cancer and the process of metastasis.
Biography
Renata Dobrila-Dintinjana is engaged in field of gastrointestinal cancers and Supportive Cancer Care for 20 years and she has authored more than 50 peerreviewed articles and over 100 reports. She is author of ten book chapters, reviewer for couple of international journals (J of Supportive Cancer Care,) and international projects in field of Cancer Research. She is also invited speaker in Postgraduated Courses regarding abdominal malignancies (Hong Kong, Moscow) and in many International Congresses and Symposia. She is member of several National Scientific Committees regarding Gastrointestinal Cancer and Supportive Cancer Care. She is serving as co-editor of Journal of Hepato-Gastroenterology and is Coordinator for Oncology section of IASGO.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version